Continued benefits of immunotherapy shown in advanced melanoma

Source: Medwire News, December 2018

medwireNews: An updated analysis of the CheckMate 067 trial shows continued survival benefits at 4 years with nivolumab plus ipilimumab or nivolumab monotherapy versus ipilimumab alone in patients with previously untreated advanced melanoma.

The study findings are published in The Lancet Oncology and were also presented at the ESMO 2018 Congress in Munich, Germany.

For the first time, the CheckMate 067 researchers also looked at outcomes in patients who discontinued the combination therapy because of treatment-related adverse events, and they found that survival in this group was similar to that among patients who did not discontinue due to adverse events.